Data shows Eli Lilly, Boehringer’s Jardiance reduces risk of CV death and hospitalisation in heart failure patients

Jardiance previously demonstrated compelling CV data in T2D patients during the EMPA-REG OUTCOME trial. Credit: Shutterstock.



  • Jardiance